(NASDAQ: RPTX) Repare Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.
Repare Therapeutics's earnings in 2025 is -$72,200,000.On average, 4 Wall Street analysts forecast RPTX's earnings for 2025 to be -$75,392,716, with the lowest RPTX earnings forecast at -$88,885,944, and the highest RPTX earnings forecast at -$59,986,621. On average, 3 Wall Street analysts forecast RPTX's earnings for 2026 to be -$32,007,193, with the lowest RPTX earnings forecast at -$30,752,009, and the highest RPTX earnings forecast at -$32,948,581.
In 2027, RPTX is forecast to generate -$26,307,282 in earnings, with the lowest earnings forecast at -$25,275,624 and the highest earnings forecast at -$27,081,026.